Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Porphyria Laboratory and Center, Departments of Preventive Medicine and Community Health, and Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555, USA.
Sci Adv. 2019 Sep 18;5(9):eaaw6127. doi: 10.1126/sciadv.aaw6127. eCollection 2019 Sep.
Erythropoietic protoporphyria (EPP) is an inherited disease caused by loss-of-function mutations of ferrochelatase, an enzyme in the heme biosynthesis pathway that converts protoporphyrin IX (PPIX) into heme. PPIX accumulation in patients with EPP leads to phototoxicity and hepatotoxicity, and there is no cure. Here, we demonstrated that the PPIX efflux transporter ABCG2 (also called BCRP) determines EPP-associated phototoxicity and hepatotoxicity. We found that ABCG2 deficiency decreases PPIX distribution to the skin and therefore prevents EPP-associated phototoxicity. We also found that ABCG2 deficiency protects against EPP-associated hepatotoxicity by modulating PPIX distribution, metabolism, and excretion. In summary, our work has uncovered an essential role of ABCG2 in the pathophysiology of EPP, which suggests the potential for novel strategies in the development of therapy for EPP.
红细胞生成性原卟啉症(EPP)是一种遗传性疾病,由亚铁螯合酶的功能丧失突变引起,亚铁螯合酶是血红素生物合成途径中的一种酶,可将原卟啉 IX(PPIX)转化为血红素。EPP 患者的 PPIX 积累会导致光毒性和肝毒性,目前尚无治愈方法。在这里,我们证明了 PPIX 外排转运蛋白 ABCG2(也称为 BCRP)决定了与 EPP 相关的光毒性和肝毒性。我们发现 ABCG2 缺乏会减少 PPIX 向皮肤的分布,从而防止与 EPP 相关的光毒性。我们还发现,ABCG2 缺乏通过调节 PPIX 的分布、代谢和排泄来保护 EPP 相关的肝毒性。总之,我们的工作揭示了 ABCG2 在 EPP 病理生理学中的重要作用,这表明在开发 EPP 治疗方法方面具有潜在的新策略。